Literature DB >> 31613633

Enhanced Oral Bioavailability and Anti-Echinococcosis Efficacy of Albendazole Achieved by Optimizing the "Spring" and "Parachute".

Chunhui Hu1,2, Zhengsheng Liu1, Chengyu Liu1, Jianhua Li, Zhixin Wang, Liuting Xu3, Cen Chen3, Haining Fan, Feng Qian1.   

Abstract

Maximizing the pharmacological efficacy of albendazole (ABZ), an anti-echinococcosis drug, is essential in the long-term treatment of patients with echinococcosis. As a weakly alkaline drug, ABZ has a pH-dependent solubility that decreases dramatically from gastric fluid (pH 1.4) to intestinal fluid (pH 6.5), where it is absorbed. In this study, we endeavored to develop an optimized tablet formulation of ABZ to improve its dissolution and oral bioavailability from two aspects: a faster initial dissolution in the gastric pH condition (i.e., the "spring") and a more prolonged drug supersaturation in the intestinal pH condition (i.e., the "parachute"). To achieve this goal, ABZ-HCl salt was selected first, which demonstrated a higher intrinsic dissolution rate under pH 1.4 compared with the ABZ free base that is used in the commercial product Albenda. Second, by comparing the ABZ supersaturation kinetics under pH 6.5 in the presence of various polymers including poly(vinylpyrrolidone) (PVP), PVP/VA, hydroxypropyl methylcellulose (HPMC), and HPMC acetate succinate (HPMC-AS), HPMC-AS was found to be the most effective crystallization inhibitor for ABZ, likely due to the hydrophobic interaction between ABZ and HPMC-AS in an aqueous environment. The newly designed tablet formulation containing ABZ-HCl and HPMC-AS showed ∼3 times higher oral bioavailability compared with that of Albenda in Beagle dogs. More significantly, the anti-echinococcosis efficacy of the improved formulation was 2.4 times higher than that of Albenda in a secondary hepatic alveolar echinococcosis Sprague-Dawley rat model. The strategy of simultaneously improving the spring and parachute of an oral formulation of ABZ, by using a highly soluble salt and an effective polymeric crystallization inhibitor, was once again proven to be a viable and readily translatable approach to optimize the unsatisfactory oral medicines due to solubility and bioavailability limitations.

Entities:  

Keywords:  albendazole; anti-echinococcosis efficacy; hepatic alveolar echinococcosis; oral bioavailability; supersaturation

Year:  2019        PMID: 31613633     DOI: 10.1021/acs.molpharmaceut.9b00851

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  3 in total

1.  Preparation, characterization, and pharmacokinetics of rivaroxaban cocrystals with enhanced in vitro and in vivo properties in beagle dogs.

Authors:  Yuanyuan Meng; Fangyun Tan; Jiaxin Yao; Yanan Cui; Yumiao Feng; Zhiping Li; Yuli Wang; Yang Yang; Wei Gong; Meiyan Yang; Xiaolong Kong; Chunsheng Gao
Journal:  Int J Pharm X       Date:  2022-05-21

2.  Improvement of the Bioavailability and Anti-hepatic Alveolar Echinococcosis Effect of Albendazole-Isethionate/Hypromellose Acetate Succinate (HPMC-AS) Complex.

Authors:  Chunhui Hu; Fabin Zhang; Haining Fan
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

3.  Hot Melt Extrusion-Triggered Amorphization as a Continuous Process for Inducing Extended Supersaturable Drug Immediate-Release from saSMSDs Systems.

Authors:  Huan Yu; Yanfei Zhang; Yinghui Ma; Huifeng Zhang; Chengyi Hao; Yong Zhang; Zhengqiang Li; Xianrong Qi; Nianqiu Shi
Journal:  Pharmaceutics       Date:  2022-03-31       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.